In a report released today, Matthew Weston from UBS maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF270.00. The company’s shares closed yesterday at ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) ...

The FDA approvals of Roche Holdings’ (OTC:RHHBY) Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific’s (NYSE:TMO) slew of advancements in ...

DelveInsight's D-Dimer Testing Market Insights report provides the current and forecast market analysis, individual leading D ...

As of October 31, 2024, Roche Holding AG had a $249.9 billion market capitalization, putting it in the 99th percentile of companies in the Pharmaceuticals industry. Roche Holding AG does not have a ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...